$MBVX CEOLIVE Insider Report | MabVax Therapeutics Holdings

Home » Hot Sectors » Biotech Stocks » $MBVX CEOLIVE Insider Report | MabVax Therapeutics Holdings

MabVax Therapeutics Holdings, Inc. is cancer diagnostic and immunotherapy company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company’s proprietary vaccines.

The Company’s lead antibody candidate HuMab 5B1 is being developed as both a diagnostic product and therapeutic agent for the diagnosis and treatment of GI cancers and specifically pancreatic cancer. The antibody product is scheduled to enter Phase I clinical trials later this year. MabVax has the exclusive license to a portfolio of therapeutic vaccines from Memorial Sloan Kettering Cancer Center. The Company has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and plans to have a third vaccine targeting neuroblastoma ready for Phase II clinical development later this year.

Disclosure: Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.

Get Alerts for Latest Featured Stocks!
Signup today and receive the newest videos. We will never share or sell your email address.
Author: Mike Elliott

Login

Lost your password?